AAAAAA

   
Results: 1-9 |
Results: 9
OPTIMIZING THE DOSE OF ZOLMITRIPTAN (ZOMIG,ASTERISK 311C90) FOR THE ACUTE TREATMENT OF MIGRAINE - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGE-FINDING STUDY
Authors: RAPOPORT AM RAMADAN NM ADELMAN JU MATHEW NT ELKIND AH KUDROW DB EARL NL
Citation: Am. Rapoport et al., OPTIMIZING THE DOSE OF ZOLMITRIPTAN (ZOMIG,ASTERISK 311C90) FOR THE ACUTE TREATMENT OF MIGRAINE - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGE-FINDING STUDY, Neurology, 49(5), 1997, pp. 1210-1218
CLINICAL EFFICACY AND TOLERABILITY OF 2.5 MG ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE
Authors: SOLOMON GD CADY RK KLAPPER JA EARL NL SAPER JR RAMADAN NM
Citation: Gd. Solomon et al., CLINICAL EFFICACY AND TOLERABILITY OF 2.5 MG ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE, Neurology, 49(5), 1997, pp. 1219-1225
SUDDEN UNEXPLAINED DEATH IN EPILEPSY - OBSERVATIONS FROM A LARGE CLINICAL DEVELOPMENT PROGRAM
Authors: LEESTMA JE ANNEGERS JF BRODIE MJ BROWN S SCHRAEDER P SISCOVICK D WANNAMAKER BB TENNIS PS CIERPIAL MA EARL NL
Citation: Je. Leestma et al., SUDDEN UNEXPLAINED DEATH IN EPILEPSY - OBSERVATIONS FROM A LARGE CLINICAL DEVELOPMENT PROGRAM, Epilepsia, 38(1), 1997, pp. 47-55
LONG-TERM TACRINE (COGNEX) TREATMENT - EFFECTS ON NURSING-HOME PLACEMENT AND MORTALITY
Authors: KNOPMAN D SCHNEIDER L DAVIS K TALWALKER S SMITH F HOOVER T GRACON S APTER JT BARNETT M BAUMEL B EISNER LS BENNETT D FORCHETTI C BLASS JP BORISON RL CELESIA GG DEXTER J DOODY R DUBOFF EA EARL NL FARLOW M HENDRIE HC FARMER M FERGUSON J FOSTER NL GREENWALD M GROENENDYK A JURKOWSKI C KATZ I PRODNER CK KNOPMAN DS MARGOLIN RA MORRIS JC RUBIN EH REYES PF RYMER MM SADOWSKY CH PAWLUCZYK S SMITH WT SOLOMON PR PENDLEBURY WW TAYLOR J THEIN SG TUTTLE P TYNDALL RJ
Citation: D. Knopman et al., LONG-TERM TACRINE (COGNEX) TREATMENT - EFFECTS ON NURSING-HOME PLACEMENT AND MORTALITY, Neurology, 47(1), 1996, pp. 166-177
CLINICAL SAFETY OF 311C90 - AGGREGATED DATA FROM PATIENTS AND VOLUNTEERS TO DATE
Authors: EARL NL
Citation: Nl. Earl, CLINICAL SAFETY OF 311C90 - AGGREGATED DATA FROM PATIENTS AND VOLUNTEERS TO DATE, European neurology, 36, 1996, pp. 8-12
EMERGING PRECLINICAL AND CLINICAL PROFILE OF 311C90 - A POSTER REVIEWAND DISCUSSION
Authors: FERRARI MD MARTIN GR EARL NL KLEIN KB
Citation: Md. Ferrari et al., EMERGING PRECLINICAL AND CLINICAL PROFILE OF 311C90 - A POSTER REVIEWAND DISCUSSION, European neurology, 36, 1996, pp. 19-23
RELATIONSHIP BETWEEN LEVEL OF INSIGHT AND SEVERITY OF DEMENTIA IN ALZHEIMER-DISEASE
Authors: MCDANIEL KD EDLAND SD HEYMAN A HARRELL L HENDERSON V WIEDERHOLT WC KARP H EVANS DA BENNETT DA CLARK DB BRANDT J GROWDON J FOSTER NL MORTIMER J MORRIS J BLASS J MAYEUX R MOHS R FERRIS S TARIOT P EARL NL FRIEDLAND R CLARK C DEKOSKY ST DOODY R WEINER M LARSON E RASKIND M BERG L VANBELLE G FILLENBAUM G
Citation: Kd. Mcdaniel et al., RELATIONSHIP BETWEEN LEVEL OF INSIGHT AND SEVERITY OF DEMENTIA IN ALZHEIMER-DISEASE, Alzheimer disease and associated disorders, 9(2), 1995, pp. 101-104
NEURAL CORRELATES OF DEMENTIA - REGIONAL BRAIN METABOLISM (FDG-PET) AND THE CERAD NEUROPSYCHOLOGICAL BATTERY
Authors: WELSH KA HOFFMAN JM EARL NL HANSON MW
Citation: Ka. Welsh et al., NEURAL CORRELATES OF DEMENTIA - REGIONAL BRAIN METABOLISM (FDG-PET) AND THE CERAD NEUROPSYCHOLOGICAL BATTERY, Archives of clinical neuropsychology, 9(5), 1994, pp. 395-409
A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: KNAPP MJ KNOPMAN DS SOLOMON PR PENDLEBURY WW DAVIS CS GRACON SI APTER JT LAZARUS CN BAKER KE BARNETT M BAUMEL B EISNER LS CASTELLS B BOLOURI R BENNETT D FORCHETTI C LEVIN A BLASS JP NOLAN KA GAINES ER RELKIN N BORISON RL DIAMOND B CELESIA GG ROSS AP DEXTER J DOODY R LIPSCOMB L KREITER K DUBOFF EA BLOCK P MARSHALL D WESTERGAARD N EARL NL WYNE SV HINMANSMITH E FARLOW M HENDRIE HC CARESS JA FARMER M HARPER JE FERGUSON J FOSTER NL BARBAS NR BLUEMLEIN LA GELB DJ BERENT S GIORDANI B GREENWALD M BERGMAN S ROGER LF GROENENDYK A WOOD M JURKOWSKI C KATZ I DOYLE S SMITH BD KELLNER C BERNSTEIN HJ BACHMAN DL KNOPMAN DS DEINARD S LANGLEY L BRIDGES S MARGOLIN RA BURGER MC WISER SL CRENSHAW C MORRIS JC RUBIN EH COATS MA REYES PF BENTZ C DOYLE LL RYMER MM BETTINGER IE LAUBINGER MP SADOWSKY CH MARTINEZ W ZUNIGA J STONE R WINNER P MATE L LESSARD C SCHNEIDER L PAWLUCZYK S SMITH WT LOSK SN MARAMBE L SOLOMON PR PENDLEBURY WW GROCCIAELLISON ME EDWARDS KR TAYLOR J CALABRESE VP HARKINS SW THEIN SG DEWAR JA WILLIAMS G DRENNAN C TUTTLE P PRINCIPI N FORD EM TYNDALL RJ KELLEY CK
Citation: Mj. Knapp et al., A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE, JAMA, the journal of the American Medical Association, 271(13), 1994, pp. 985-991
Risultati: 1-9 |